Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
09/2005
09/09/2005WO2005082362A1 Therapeutic combinations
09/09/2005WO2005082361A1 Roflumilast and glycopryrronium combination
09/09/2005WO2005082360A1 Peroral preparations containing vitamin e
09/09/2005WO2005082359A2 Use of beta-lapachone for the treatment of pancreatic cancer
09/09/2005WO2005082358A2 Use of beta-lapachone as a broad spectrum anti-cancer agent
09/09/2005WO2005082357A1 Use of beta-lapachone for treating hematologic tumors
09/09/2005WO2005082356A2 Use of beta-lapachone for the treatment of lung cancer
09/09/2005WO2005082355A2 Use of beta-lapachone for treatment of colon cancer
09/09/2005WO2005082354A1 Beta-lapachone and s-phase drug combinations for cancer treatment
09/09/2005WO2005082353A2 Use of beta-lapachone for treating or preventing cancer
09/09/2005WO2005082352A1 Oxydecahydronaphthalene modulators of hm74
09/09/2005WO2005082351A1 Therapeutic agent for neurodegenerative disorder
09/09/2005WO2005082350A1 Furosemide derivatives as modulators of hm74 and their use for the treatment of inflammation
09/09/2005WO2005082349A1 Composition for the treatment of obesity comprising fumagillol derivative
09/09/2005WO2005082348A2 Inhibitors of dipeptidylpeptidase iv for regulating glucose metabolism
09/09/2005WO2005082347A1 Use of methylene amide derivatives in cardiovascular disorders
09/09/2005WO2005082346A1 Use of cysteinyl leukotriene 2 receptor antagonists
09/09/2005WO2005082345A2 Targeting the reverse mode of the na+/ca2+ exchanger for the treatment of neurodegenerative conditions such as alzheimers and parkinsons diseases, multiple sclerosis and amyotropic lateral sclerosis; diabetic retinopathy, epilepsy and ischemia
09/09/2005WO2005082344A1 Lhr1 activators as medicaments
09/09/2005WO2005082343A2 Amines and amides for the treatment of diseases
09/09/2005WO2005082342A1 Use of targeted oxidative therapeutic formulation in treatment of viral diseases
09/09/2005WO2005082341A2 NON-PEPTIDYL AGENTS WITH pHSP20-LIKE ACTIVITY, AND USES THEREOF
09/09/2005WO2005082340A2 Modulation of inflammatory and metastatic processes
09/09/2005WO2005082338A2 Prodrugs for the intravenous administration of proton pump inhibitors
09/09/2005WO2005082337A2 Compositions comprising prodrugs of proton pump inhibitors
09/09/2005WO2005082334A1 Sustained-release cream preparation
09/09/2005WO2005082331A2 Extended release tablets of clarithromycin
09/09/2005WO2005082330A2 Co-precipitated amorphous cefditoren pivoxil and dosage forms comprising the same
09/09/2005WO2005082329A2 Process for the preparation of solid dosage forms of valsartan and hydrochlorthiazide
09/09/2005WO2005082327A1 Topical compositions associating sodium hyaluronate fragments and retinoid useful for cosmetic and medical dermatology
09/09/2005WO2005082169A1 Raw material for diet processed food and diet processed food from the raw material
09/09/2005WO2005082144A1 Methylation inhibitor compounds
09/09/2005WO2005082143A1 Compositions and methods for sleep regulation
09/09/2005WO2005082079A2 Tetracyclic lactam derivatives and uses thereof
09/09/2005WO2005082054A2 Combinations for the treatment of fungal infections
09/09/2005WO2005082049A2 Artificial biocompatible material as a support for cells in a retinal implant
09/09/2005WO2005082048A2 Dissolvable film and method of manufacture
09/09/2005WO2005082032A2 Treatment of attention disorders
09/09/2005WO2005082023A2 Heterocyclic self-immolative linkers and conjugates
09/09/2005WO2005082006A2 Method for providing antimicrobial composite yarns, composite fabrics and articles made therefrom
09/09/2005WO2005081960A2 Inhibitors of protein tyrosine phosphatase 1b
09/09/2005WO2005081954A2 Inhibitors of protein tyrosine phosphatase 1b
09/09/2005WO2005081897A2 Methods and compositions comprising non-peptide small molecules that solubilize beta amyloid peptide fiber
09/09/2005WO2005081821A2 Polymorphic forms of 6-11 bicyclic ketolide derivatives
09/09/2005WO2005081816A2 Method of preventing fibrin clots in pulmonary tissue through the use of aerosolized anticoagulants
09/09/2005WO2005081753A2 Nitric oxide-releasing molecules
09/09/2005WO2005081752A2 Nitric oxide-releasing polymers
09/09/2005WO2005081742A2 Testosterone oral dosage formulations and associated methods
09/09/2005WO2005081687A2 Human hinge core mimetibodies, compositions, methods and uses
09/09/2005WO2005081649A2 Preparation for reducing protein deficiency in an organism and method for the production thereof
09/09/2005WO2005070922A3 Bis-indole pyrroles useful as antimicrobials agents
09/09/2005WO2005069933A3 Methods of treating an inflammatory-related disease
09/09/2005WO2005065722A3 Reducing arthritis and lameness in subjects by growth hormone releasing hormone (ghrh) supplementation
09/09/2005WO2005063757A3 Novel crystalline forms of temozolomide
09/09/2005WO2005062985A3 Di-ester prodrugs of camptothecin, process for their preparation and their therapeutical applications
09/09/2005WO2005062913A3 Triplide 5,6-derivatives as immunomodulators and anticancer agents
09/09/2005WO2005061493A3 Polymorphic form b2 of ziprasidone base
09/09/2005WO2005061468A8 Halogenated biaryl heterocyclic compounds and methods of making and using the same
09/09/2005WO2005060976A3 Use of superoxide dismutase mimetics and reductase glutathione in the form of anticancer drugs
09/09/2005WO2005060949A3 Selective norepinephrine reuptake inhibitors for the treatment of hot flashes, impulse control disorders and personality change due to a general medical condition
09/09/2005WO2005060711A3 Methods of treating a disorder
09/09/2005WO2005058884A3 Cyclopropane compounds and pharmaceutical use thereof
09/09/2005WO2005058867A8 Benzothiophene-and thiochromene containing phenethanolamine derivatives for the treatment of respiratory disorders
09/09/2005WO2005058819A8 Polymorphic forms of tegaserod base and salts thereof
09/09/2005WO2005053669A8 Use of omega-3 polyunsaturated fatty acids for sleep apnoea
09/09/2005WO2005051410B1 Hepatitis c virus inhibitors
09/09/2005WO2005051344A3 Oral solid instant-release dosage forms comprising finasteride and an anionic surfactant-methods of manufacturing thereof
09/09/2005WO2005051286A3 Stable ready-for-use injectable solution of 9-((1,3-dihydroxypropan-2-yloxy) methyl)-2-amine-1h-purin-6(9h)-one.
09/09/2005WO2005048810A3 Sigma-2 receptor radiotracers for imaging the proliferative status of solid tumors
09/09/2005WO2005046708A8 Selective inhibitors of nuclear factor-kb activation and uses thereof
09/09/2005WO2005046611A3 Glucoimidazole and polyhydroxycyclohexenyl amine derivatives to treat gaucher disease
09/09/2005WO2005046603A3 Pyridine compounds
09/09/2005WO2005044243A8 Transdermal analgesic systems having reduced abuse potential
09/09/2005WO2005044192A3 Triazole compounds and uses related thereto
09/09/2005WO2005044176A3 Compositions containing phosphatidic acid, methods of use thereof, methods of manufacture thereof, and articles of manufacture containing same
09/09/2005WO2005042692A3 A method of inhibiting the expression of genes which mediate cellular cholesterol influx in animal cells and inhibiting the production of proteins resulting from the expression of such genes using cholesterol absorption inhibitors
09/09/2005WO2005032493A3 Amide compounds as ion channel ligands and uses thereof
09/09/2005WO2005030183A3 A method for the preparation of atorvastatin calcium tablets
09/09/2005WO2005030151A3 Compounds and compositions as protein kinase inhibitors
09/09/2005WO2005023175B1 Stable pharmaceutical composition of fluoroether compound for anesthetic use, method for stabilizing a fluoroether compound, use of stabilizer agent for precluding the degradation of a fluoroether compound
09/09/2005WO2005021708A3 Bisphosphonates for prophylaxis and therapy against bioterrorism agents
09/09/2005WO2005020984A3 Method of reducing the risk of oxidative stress
09/09/2005WO2005018568A3 Inhibitors of cathepsin s
09/09/2005WO2005016271A3 Composition comprising a zeolite compound for treatment of diseases
09/09/2005WO2005016262A3 Methods for administering aripiprazole
09/09/2005WO2005014584A8 3-(indol-1-yl)-4-(indol-3-yl)-pyrrole-2,5-diones,3-(benzimidazol-1-yl)-4-(indol-3-yl)-pyrrole-2,5-diones, and 3-(indolin-1-yl)-4-(indol-3-yl)-pyrrole-2,5-diones; their preparation and use as modulators of apoptosis
09/09/2005WO2005011578A3 Preoperative treatment of post operative pain
09/09/2005WO2005009539A3 Compounds for inflammation and immune-related uses
09/09/2005WO2005009373A3 Tyrosine kinase inhibitors
09/09/2005WO2005009207A3 Methods for delaying or inducing labor
09/09/2005WO2005007122A3 Polymer stabilization
09/09/2005WO2005007101A3 Compositions and methods for the enhanced uptake of therapeutic agents through the bladder epithelium
09/09/2005WO2005007085A3 Pyrazolo pyrimidine derivatives and methods of use thereof
09/09/2005WO2005000320A3 Use of double-stranded ribonucleic acid for inducing cell lysis
09/09/2005WO2004112763A3 Inhibition of protein kinase c-mu (pkd) as a treatment for cardiac hypertrophy and heart failure
09/09/2005WO2004106494A3 A preservative and method for preserving cells
09/09/2005WO2004096144A3 Compositions and methods for induction of opioid receptors
09/09/2005WO2004094652A3 Zinc-based screening test and kit for early diagnosis of prostate cancer
09/09/2005WO2004091484A3 Use of orsaponin [3beta, 16beta, 17 alpha-trihydroxycholost-5-en­22-one 16-0-(2-0-4-methoxybenzoyl-beta-d-xylopyranosyl)-(1->3)-(2-0­acetyl-alpha-l-arabinopyranoside)] or osw-1 and its derivatives for cancer therapeutics
09/09/2005WO2004087862A3 Tak1-mediated inhibition of osteogenesis
1 ... 4548 4549 4550 4551 4552 4553 4554 4555 4556 4557 4558 4559 4560 4561 4562 4563 4564 4565 4566 4567 4568 ... 7860